JOHNSON & JOHNSON
JNJNYSE · SIC 2834
$253.04
↑ +1.2%Jul 17 close · end-of-day
Price
1Y↑ +57.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$618.7B
Enterprise Value
$651.7B
P/E
29.3
P/S
6.4
P/B
7.6
EV/EBITDA
—
PEG
1.6
FCF Yield
2.9%
Dividend Yield
2.1%
Revenue (TTM)
$96.4B
Net Income (TTM)
$21.0B
Free Cash Flow (TTM)
$17.8B
Gross Margin
67.8%
Operating Margin
—
Net Margin
21.8%
ROE
25.9%
ROIC
—
Debt / Equity
0.7
Net Cash
-$32.9B
Return 1Y
+59.1%
Company profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands. Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis. MedTech segment provides electrophysiology products to treat cardiovascular diseases.
- CEO
- Joaquin Duato
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 152,700
- Headquarters
- New Jersey
- Website
- jnj.com
Management & directors
- Wengel Kathryn EEVP, Chief TO and Risk Officer
- Reed John CEVP, Innovative Medicine, R&D
- Decker Robert JVP Corporate Controller
- Schmid TimothyEVP, WW Chair, MedTech
- Broadhurst VanessaEVP, Global Corp Affairs
- Swanson James D.EVP, CIO
- Wolk Joseph JExec VP, CFO
- Duato JoaquinCEO and Chairman of the Board
- Forminard ElizabethExecutive VP, General Counsel
- Mulholland KristenEVP, Chief HR Officer
- Taubert Jennifer LEVP, WWC. Innovative Medicine
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-10-14
JNJ Q1 2026 Earnings
Period ends 2026-03-29
MetricActualYoY
Revenue$24.1B↑ +9.9%
Diluted EPS$2.14↓ -52.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $82.6B | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Gross profit | $54.2B | $55.3B | $55.4B | $58.6B | $61.4B | $63.9B |
| Operating income | — | — | — | — | — | — |
| Net income | $14.7B | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Diluted EPS | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Operating cash flow | $23.5B | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Free cash flow | $20.2B | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| Gross margin | 65.6% | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Operating margin | — | — | — | — | — | — |
| Net margin | 17.8% | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.4B | $22.5B | $22.5B | $21.9B | $23.7B | $24.0B | $24.6B | $24.1B |
| Gross profit | $15.6B | $15.5B | $15.4B | $14.5B | $16.1B | $16.7B | $16.6B | $16.0B |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $4.7B | $2.7B | $3.4B | $11.0B | $5.5B | $5.2B | $5.1B | $5.2B |
| Diluted EPS | $1.93 | $1.11 | $1.41 | $4.54 | $2.29 | $2.12 | $2.08 | $2.14 |
| Operating cash flow | $5.6B | $8.0B | $7.0B | $4.2B | $3.9B | $9.2B | $7.3B | $2.5B |
| Free cash flow | $4.7B | $7.0B | $5.4B | $3.4B | $2.8B | $8.0B | $5.5B | $1.5B |
| Gross margin | 69.4% | 69.0% | 68.3% | 66.4% | 67.9% | 69.6% | 67.6% | 66.3% |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 20.9% | 12.0% | 15.2% | 50.2% | 23.3% | 21.5% | 20.8% | 21.8% |
Company news
Jul 20, 2026
- 1h agoThe Robot Maker's Paradoxtrefis.com
- 2h agoReading Between The Lines Of JNJ Stock's Latest Calltrefis.com
- 2h agoMerck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.finance.yahoo.com
- 2h agoWhat's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?trefis.com
- 3h agoJim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD247wallst.com
- 3h agoEli Lilly Stock And The Price Of Confidencetrefis.com
- 8h agoShould You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?finance.yahoo.com
- 8h agoBeat the Market the Zacks Way: Liquidia, BILL, Colgate-Palmolive in Focusfinance.yahoo.com
- 13h agoBear of the Day: J&J Snack Foods (JJSF)finance.yahoo.com
- 15h agoWhat Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.finance.yahoo.com
Jul 19, 2026
- 22h agoIs It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?fool.com
- 1d agoMy 2 Favorite Dividend Kings to Buy Right Nowfool.com
- 1d agoJohnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Devicefinance.yahoo.com
- 1d ago3 Biggest Pharma Giants: Buy, Sell or Hold?247wallst.com
- 1d agoWould You Rather Earn $55,000 Today or $110,000 in 20 Years?247wallst.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Wengel Kathryn E· EVP, Chief TO and Risk Officer | Sale | 10,000 | $241.15 | $2.4M | filing |
| 2026-06-11 | Wengel Kathryn E· EVP, Chief TO and Risk Officer | Option exercise | 10,000 | $115.67 | $1.2M | filing |
| 2026-05-01 | REED JOHN C· EVP, Innovative Medicine, R&D | Tax withholding | 11,002 | $229.85 | $2.5M | filing |
| 2026-05-01 | REED JOHN C· EVP, Innovative Medicine, R&D | Option exercise | 25,255 | $0.00 | $0.00 | filing |
| 2026-02-27 | Decker Robert J· VP Corporate Controller | Sale | 4,075 | $247.87 | $1.0M | filing |
| 2026-02-27 | Decker Robert J· VP Corporate Controller | Option exercise | 4,075 | $115.67 | $471,355.25 | filing |
| 2026-02-20 | Schmid Timothy· EVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $324,762.52 | filing |
| 2026-02-18 | Schmid Timothy· EVP, WW Chair, MedTech | Sale | 13,625 | $244.20 | $3.3M | filing |
| 2026-02-18 | Schmid Timothy· EVP, WW Chair, MedTech | Sale | 8,998 | $244.53 | $2.2M | filing |
| 2026-02-18 | Schmid Timothy· EVP, WW Chair, MedTech | Option exercise | 13,625 | $115.67 | $1.6M | filing |
| 2026-02-18 | Schmid Timothy· EVP, WW Chair, MedTech | Option exercise | 8,998 | $129.51 | $1.2M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Sale | 33,386 | $242.75 | $8.1M | filing |
| 2026-02-17 | REED JOHN C· EVP, Innovative Medicine, R&D | Sale | 29,927 | $243.00 | $7.3M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Sale | 24,961 | $242.68 | $6.1M | filing |
| 2026-02-17 | REED JOHN C· EVP, Innovative Medicine, R&D | Sale | 21,721 | $243.00 | $5.3M | filing |
| 2026-02-17 | Swanson James D.· EVP, CIO | Sale | 20,521 | $242.70 | $5.0M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Sale | 19,241 | $242.99 | $4.7M | filing |
| 2026-02-17 | REED JOHN C· EVP, Innovative Medicine, R&D | Option exercise | 29,927 | $156.15 | $4.7M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Option exercise | 33,386 | $131.94 | $4.4M | filing |
| 2026-02-17 | REED JOHN C· EVP, Innovative Medicine, R&D | Option exercise | 21,721 | $157.92 | $3.4M | filing |
| 2026-02-17 | Swanson James D.· EVP, CIO | Option exercise | 20,521 | $164.62 | $3.4M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Sale | 12,066 | $242.87 | $2.9M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Option exercise | 19,241 | $115.67 | $2.2M | filing |
| 2026-02-17 | Wolk Joseph J· Exec VP, CFO | Option exercise | 12,066 | $129.51 | $1.6M | filing |
| 2026-02-17 | Broadhurst Vanessa· EVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.5M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.